Early Phase Trial of Gene Engineered T Cells Targeting Cancer Testis Antigens in Multiple Myeloma

Adaptimmune today announces the release of preliminary results from an early phase clinical study using patients' own T cells that have been genetically altered to attack multiple myeloma cells.

http://floridabiotechnews.com/biotech/early-phase-trial-of-gene-engineered-t-cells-targeting-cancer-testis-antigens-in-multiple-myeloma/11476/?#038;#038;